



The Pathophysiology of Preeclampsia

Guest Editor:

Prof. Dr. Marzena Laskowska

Department of Obstetrics and
Perinatology, Medical University
of Lublin, Lublin, Poland

Deadline for manuscript
submissions:

closed (31 January 2024)

Message from the Guest Editor

Preeclampsia is a multisystem, specific for human pregnancy, disease, and is a cause of serious complications for both the pregnant woman and her baby. Preeclampsia may lead to foetal growth restriction (FGR), premature birth, or intrauterine foetal death. In severe cases, an attack of eclamptic seizures, premature separation of the placenta, DIC, intracranial haemorrhage, HELLP syndrome, renal failure, and even maternal and foetal death may occur.

The aim of this Special Issue is to provide a review of aetiopathogenesis of preeclampsia. Laboratory and clinical researchers are welcomed to submit their works that contribute to better pregnancy outcomes in preeclamptic women. Thus, all original research articles or reviews on topics related to pregnancy in women with preeclampsia and HELLP syndrome are welcome in this Special Issue. Topics will include:

- Preeclampsia and hypertension in pregnant women—aetiopathogenesis, pathophysiology, causes, complications;
- HELLP syndrome—diagnosis, pathophysiology;
- Placenta in preeclampsia—what has gone wrong;
- Foetal complications.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](https://twitter.com/Biomed_MDPI)